|Mr. Michael A. Mussallem||3.38M||48.81M||64|
|Mr. Scott B. Ullem||1.32M||N/A||50|
|Mr. Donald E. Bobo Jr.||1.27M||4.56M||55|
|Mr. Larry L. Wood||1.36M||5.46M||51|
|Ms. Catherine M. Szyman||1.36M||N/A||50|
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patients diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems. Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patients heart function in surgical and intensive care settings; pulmonary artery catheters; and Oximetry Central Venous Catheters for continuous measurement of central venous oxygen saturation. Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Edwards Lifesciences Corporation’s ISS Governance QualityScore as of October 15, 2017 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 2; Compensation: 4.